(MENAFN- EIN Presswire) market-scope.jpeg" width="300" height="88" alt="Heplisav B market Report 2025 : Market Size, Trends, And Global Forecast 2025-2034" style="max ...

The company’s Heplisav-B vaccine, which is the only two-dose adult Hepatitis B vaccine, reported a significant year-over-year sales increase, reaching the upper end of the guidance for 2024.

HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.

Dynavax Technologies Corporation (NASDAQ:DVAX), a profitable pharmaceutical company with strong financial health according to ...

Dynavax Technologies Corporation (the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced the following changes to its Board of ...

Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million Enrollment completed in Phase 1/2 shingles trial; top line results expected in Q3 2025 New $ ...

"We are excited to announce that HEPLISAV-B has achieved record annual revenue in 2024, reflecting 26% growth year-over-year, and positioning us at the upper tier of our updated guidance range.

EMERYVILLE, Calif. - Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company with a ...

Dynavax Technologies (NASDAQ:DVAX – Get Free Report) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday. Separately, HC ...

An update from Dynavax ( (DVAX) ) is now available. Dynavax announced a 26% year-over-year increase in net product revenue for HEPLISAV-B in 2024, reaching approximately $268 million. The company ...